General pharmacology of pergolide in animals. 1st communication: cardiovascular, respiratory and autonomic nervous system studies.
Pergolide mesylate ((8 beta)-8-[(methylthio)methyl]-6-propylergoline monomethanesulfonate, LY 127,809, CAS 66104-23-2) is a novel and potent dopamine agonist marketed for treating the symptoms of Parkinson's disease. The potential secondary pharmacological effects of this agent on the cardiovascular, respiratory, and the autonomic nervous systems were examined. Pergolide exhibited significant pharmacological effects in cardiovascular and autonomic tests at high oral or intravenous doses. The reference dopamine agonist, bromocriptine, exhibited effects qualitatively similar to, but at doses generally higher than, pergolide, in parallel with its lower therapeutic potency relative to pergolide. In summary, these studies confirm the pharmacological selectivity of pergolide at low doses, and indicate the potential for secondary pharmacological side effects upon cardiovascular function at significant multiples of the clinical dose.
Williams
P
P
Lilly Research Laboratories, Eli Lilly and Company, Greenfield, Indiana.
Colbert
W
W
Turk
J
J
Owen
N
N
D000109:Acetylcholine / Q000494:pharmacology; D000284:Administration, Oral; D000758:Anesthesia; D000818:Animals; D001341:Autonomic Nervous System / Q000187:drug effects*; D001971:Bromocriptine / Q000494:pharmacology; D002339:Carotid Arteries / Q000502:physiology; D003655:Decerebrate State / Q000503:physiopathology; D004285:Dogs; D005260:Female; D006168:Guinea Pigs; D006439:Hemodynamics / Q000187:drug effects*; D066298:In Vitro Techniques; D008297:Male; D009130:Muscle, Smooth / Q000187:drug effects; D009638:Norepinephrine / Q000494:pharmacology; D010479:Pergolide / Q000494:pharmacology*; D051381:Rats; D011919:Rats, Inbred Strains; D012119:Respiration / Q000187:drug effects*; D014630:Vagus Nerve / Q000502:physiology
D010479:Pergolide; D001971:Bromocriptine; D000109:Acetylcholine; D009638:Norepinephrine